View More Recent Stories

Sep 5, 2024 06:13AM China Detains AstraZeneca (AZN) Staff in Data, Drug-import Probes - Bloomberg
Sep 3, 2024 06:13AM AstraZeneca (AZN) advances ambition to improve standards of care in multiple cancer types at WCLC and ESMO 2024
Aug 16, 2024 07:00AM AstraZeneca's (AZN) IMFINZI approved in the US for the treatment of resectable non-small cell lung cancer before and after surgery
Aug 15, 2024 07:02AM AstraZeneca’s (AZN) IMFINZI Granted FDA Priority Review and Breakthrough Therapy Designation
Aug 13, 2024 07:16AM AstraZeneca (AZN): Enhertu approved in China for patients with previously treated HER2-positive advanced or metastatic gastric cancer
Aug 12, 2024 08:12AM AstraZeneca (AZN) PT Raised to $95 at TD Cowen
Jul 29, 2024 07:07AM AstraZeneca (AZN): Fixed-duration CALQUENCE plus venetoclax, with or without obinutuzumab, significantly improved PFS in 1st-line chronic lymphocytic leukemia in AMPLIFY Phase III trial
Jul 25, 2024 03:59PM AstraZeneca (AZN) reports FDA AdCom reviewed Imfinzi for treatment of resectable non-small cell lung cancer based on AEGEAN Phase III trial results
Jul 25, 2024 05:25AM AstraZeneca (AZN) Tops Q2 EPS by 99c; offers guidance
Jul 24, 2024 04:46AM AstraZeneca (AZN) July weekly 79 straddle priced into quarter results
Jul 15, 2024 05:55AM AstraZeneca (AZN) Completes Acquisition of Amolyt Pharma
Jul 12, 2024 02:32AM Morgan Stanley Reiterates Overweight Rating on AstraZeneca (AZN:LN) (AZN)
Jul 10, 2024 06:30AM Morgan Stanley is out with its 'Top Stock Picks' list for Europe
Jul 5, 2024 05:54AM AstraZeneca's (AZN) Tagrisso plus chemotherapy approved in EU as new 1st-line treatment for patients with EGFR-mutated advanced lung cancer
Jul 1, 2024 06:00AM AstraZeneca (AZN) reports Lynparza plus Imfinzi recommended for approval in the EU by CHMP
Jun 26, 2024 05:52AM AstraZeneca's (AZN) Tagrisso plus chemotherapy approved in China as 1st-line treatment for patients with EGFR-mutated advanced lung cancer
Jun 25, 2024 07:03AM AstraZeneca (AZN): IMFINZI demonstrated statistically significant and clinically meaningful improvement in EFS and OS for muscle-invasive bladder cancer in NIAGARA Phase III trial
Jun 25, 2024 05:57AM AstraZeneca (AZN) reports Imfinzi showed statistically significant improvement in event-free survival and overall survival for muscle-invasive bladder cancer in NIAGARA Phase III trial
Jun 25, 2024 05:56AM AstraZeneca (AZN) Issues Update on ADJUVANT BR.31 Phase III trial of Imfinzi in non-small cell lung cancer
Jun 25, 2024 05:56AM AstraZeneca (AZN) reports Tagrisso plus chemotherapy approved in Japan as new 1st-line treatment for patients with EGFR-mutated advanced lung cancer
Jun 20, 2024 06:09AM AstraZeneca (AZN) announces Truqap plus Faslodex approved in the EU
Jun 18, 2024 06:09AM AstraZeneca (AZN) announces CAPItello-290 Phase III trial did not meet endpoints
Jun 17, 2024 07:03AM AstraZeneca (AZN) announces IMFINZI plus chemotherapy approved in the US
Jun 10, 2024 06:03AM AstraZeneca (AZN): TAGRISSO granted Priority Review in the US for patients with unresectable, Stage III EGFR-mutated lung cancer
Jun 10, 2024 04:36AM AstraZeneca (AZN) announces Tagrisso granted FDA Priority Review for patients with unresectable, Stage III EGFR-mutated lung cancer
View More Recent Stories